U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD Draft Guidance for Industry December 2014

Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2014-D-1891
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This guidance describes how a prospective abbreviated new drug application (ANDA) applicant 19 may request a letter stating that FDA has determined: (1) that the prospective applicant’s 20 bioequivalence (BE) study protocol contains safety protections comparable to those in the risk 21 evaluation and mitigation strategy (REMS) with elements to assure safe use (ETASU) applicable 22 to the reference listed drug (RLD), and (2) that FDA will not consider it a violation of the REMS 23 for the RLD sponsor to provide a sufficient quantity of the RLD to the interested generic firm or 24 its agent to allow the firm to perform the testing necessary to support its ANDA.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2014-D-1891.

Back to Top